Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

  • E. Felip
  • , B. C. Cho
  • , V. Gutiérrez
  • , A. Alip
  • , B. Besse
  • , S. Lu
  • , A. I. Spira
  • , N. Girard
  • , R. Califano
  • , S. M. Gadgeel
  • , J. C.H. Yang
  • , S. Yamamoto
  • , K. Azuma
  • , Y. J. Kim
  • , K. H. Lee
  • , P. Danchaivijitr
  • , C. G. Ferreira
  • , Y. Cheng
  • , M. A.N. Sendur
  • , G. C. Chang
    • C. C. Wang, K. Prabhash, Y. Shinno, D. Stroyakovskiy, L. Paz-Ares, J. R. Rodriguez-Cid, C. Martin, M. R.G. Campelo, H. Hayashi, D. Nguyen, P. Tomasini, M. Gottfried, C. Dooms, A. Passaro, M. Schuler, A. C.Z. Gelatti, S. Owen, K. Perdrizet, S. H.I. Ou, J. C. Curtin, J. Zhang, M. Gormley, T. Sun, A. Panchal, M. Ennis, E. Fennema, M. Daksh, S. Sethi, J. M. Bauml, S. H. Lee

Research output: Contribution to journal › Article › peer-review

75   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science